Healthdirect Free Australian health advice you can count on.
Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately
healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.
NSW Health Alert: Any patients who have received dental treatment from Mr Safuan (Steven) Hasic at 70 Victoria Ave, Mortdale NSW 2223 may
be at risk of blood-borne viruses and should see their GP for precautionary testing. More information is available from
NSW Health
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
DBL Bortezomib Powder for Injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
DBL Bortezomib Powder for Injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
DBL Bortezomib Powder for Injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
DBL Bortezomib Powder for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DBL Bortezomib Powder for Injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
DBL Bortezomib Powder for Injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
DBL Bortezomib Powder for Injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
DBL Bortezomib Powder for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Bortezomib Powder for Injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
Bortezomib Powder for Injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
Bortezomib Powder for Injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
Bortezomib Powder for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DBL Bortezomib Powder for Injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
DBL Bortezomib Powder for Injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
DBL Bortezomib Powder for Injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
DBL Bortezomib Powder for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
